Abstract: The present invention provides an improved method of chromatographically separating the isomers of (1R,rR)-atracurium salts by high-performance liquid chromatography (HPLC), in the absence of a strong acid. The separation is preferably performed on a silica gel HPLC column using an eluent containing an organic solvent, a polar aprotic co-solvent and a weak organic acid.
Abstract: An isolated and pure crystalline rotigotine base of polymorph Form I, and processes for producing the crystalline rotigotine base are disclosed. Also disclosed is a transdermal patch for the delivery of rotigotine base using the disclosed isolated and pure form of rotigotine base, which can be used in treatment of Parkinson's Disease and other disorders ameliorated or treated by rotigotine, including restless leg syndrome.
Abstract: Provided are novel salts of 2-(1-azabicyclo-[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one, methods of using such salts, and processes for producing such salts.
Abstract: The present invention provides a process of producing cisatracurium compounds, e.g., cisatracurium besylate, from isoquinolinium salts of the structural formula (VIIA) wherein X? is an anion and R is H or a C1-C6 alkyl, or an activated form of the carboxylic acid with 1,5-pentanediol to form a cisatracurium salt, optionally via an intermediate compound (VIII). The cisatracurium compounds can be purified using simple techniques to afford pure cisatracurium besylate without the need for HPLC purification.
Abstract: The present invention provides novel isoquinolinium compounds, methods of producing the isoquinolinium compounds, and methods for converting them into cisatracurium, e.g., cisatracurium besylate. The isoquinolinium compounds of the present invention can be obtained in the form of solids, which can be purified using simple techniques and can be used to afford pure cisatracurium besylate without HPLC purification.
Abstract: The present invention provides an improved method for obtaining cisatracurium besylate, which preferably chromatographically separating cisatracurium besylate from a mixture of (1R,1?R)-atracurium isomers via flash chromatography.
Abstract: The present invention provides R,R?-atracurium salts, processes for producing and purifying such salts, and methods of using such salts to produce highly pure cisatracurium besylate.
Type:
Grant
Filed:
October 7, 2008
Date of Patent:
January 15, 2013
Assignee:
CHEMAGIS Ltd.
Inventors:
Oded Arad, Ofer Sharon, Elena Ostrovsky
Abstract: An isolated and pure crystalline rotigotine base of polymorph Form I, and processes for producing the crystalline rotigotine base are disclosed. Also disclosed is a transdermal patch for the delivery of rotigotine base using the disclosed isolated and pure form of rotigotine base, which can be used in treatment of Parkinson's Disease and other disorders ameliorated or treated by rotigotine, including restless leg syndrome.
Abstract: Provided are novel salts of 2-(1-azabicyclo-[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one, methods of using such salts, and processes for producing such salts.
Type:
Grant
Filed:
May 28, 2008
Date of Patent:
December 18, 2012
Assignee:
Chemagis Ltd.
Inventors:
Tang Wensheng, Zhang Xingzhong, He Xungui, Yuan Wang, Joseph Kaspi
Abstract: Disclosed herein are methods of obtaining highly pure 5-azacytidine, which contains minimal amounts of degradation impurities and methods of assessing the impurity profile of the degradation of cytidine analogues, such as 5-azacytidine
Type:
Application
Filed:
July 23, 2008
Publication date:
November 24, 2011
Applicant:
CHEMAGIS LTD.
Inventors:
Alex Weisman, Lior Zelikovitch, Oded Friedman, Josef Manascu
Abstract: A process for preparing pure levocetirizine and salts thereof, e.g., the levocetirizine dihydrochloride, and a pharmaceutical composition comprising levocetirizine dihydrochloride produced by the process are disclosed.
Abstract: The present invention provides compounds which are useful, e.g., as reference markers for analyzing the purity of cisatracurium and salts thereof, a test method for determining the said purity and processes for preparing reference markers.
Type:
Application
Filed:
April 28, 2009
Publication date:
August 4, 2011
Applicant:
CHEMAGIS Ltd.
Inventors:
Oded Arad, Vladimir Naddaka, Eyal Klopfer, Shady Saeed, Lior Shahar, Vitaly Shteinman
Abstract: Provided is a process for the epimerization of the cis isomer of atovaquone, atovaquone intermediates and isomeric mixtures thereof into their corresponding trans-isomers resulting in higher yield of pure atovaquone.
Abstract: Provided is a process for producing highly pure 4-amino-1-isobutyl-1H-imidazo[4,5-c]quinoline (imiquimod), which includes reacting 4-chloro-1-isobutyl-1H-imidazo[4,5-c]quinoline with a non-gaseous amine precursor. Also provided are methods for isolating highly pure imiquimod. Further provided are intermediates useful in the production of imiquimod, methods for producing such intermediates, and methods for obtaining imiquimod from such intermediates.
Type:
Grant
Filed:
January 24, 2007
Date of Patent:
May 17, 2011
Assignee:
Chemagis Ltd.
Inventors:
Vladimir Naddaka, Eyal Klopfer, Shady Saeed, Stephen Cherkez, Oded Arad
Abstract: The present invention provides a process of producing cisatracurium compounds, e.g., cisatracurium besylate, from isoquinolinium salts of the structural formula (VIIA) wherein X? is an anion and R is H or a C1-C6 alkyl, or an activated form of the carboxylic acid with 1,5-pentanediol to form a cisatracurium salt, optionally via an intermediate compound (VIII). The cisatracurium compounds can be purified using simple techniques to afford pure cisatracurium besylate without the need for HPLC purification.
Abstract: The present invention provides R,R?-atracurium salts processes for producing and purifying such salts, and methods of using such salts to produce highly pure cisatracurium besylate.
Type:
Application
Filed:
October 7, 2008
Publication date:
September 16, 2010
Applicant:
CHEMAGIS LTD.
Inventors:
Oded Arad, Ofer Sharon, Elena Ostrovsky
Abstract: An isolated and pure crystalline rotigotine base of polymorph Form I, and processes for producing the crystalline rotigotine base are disclosed. Also disclosed is a transdermal patch for the delivery of rotigotine base using the disclosed isolated and pure form of rotigotine base, which can be used in treatment of Parkinson's Disease and other disorders ameliorated or treated by rotigotine, including restless leg syndrome.
Abstract: Provided is a process for producing highly pure midazolam and salts thereof, and a pharmaceutical composition containing the highly pure midazolam and/or a salt thereof.